167 related articles for article (PubMed ID: 16476317)
1. [Treatment of cutaneous T-cell lymphomas with bexarotene].
Lasa O; Izu R; Acebo E; Eguino P; Díaz-Pérez JL
Actas Dermosifiliogr; 2005 Dec; 96(10):669-73. PubMed ID: 16476317
[TBL] [Abstract][Full Text] [Related]
2. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
3. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
4. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
Pileri A; Delfino C; Grandi V; Pimpinelli N
Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
[TBL] [Abstract][Full Text] [Related]
5. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
6. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
7. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
9. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
Sherman SI
Clin Lymphoma; 2003 Mar; 3(4):249-52. PubMed ID: 12672276
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Mehta N; Wayne AS; Kim YH; Hale GA; Alvarado CS; Myskowski P; Jaffe ES; Busam KJ; Pulitzer M; Zwerner J; Horwitz S
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):20-5. PubMed ID: 22001256
[TBL] [Abstract][Full Text] [Related]
11. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
Avilés Pérez MD; Luna López V; Rodríguez Nevado I; de Argila Fernández-Durán D; Díaz Pérez de Madrid J
An Med Interna; 2007 Dec; 24(12):595-8. PubMed ID: 18278999
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
14. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
16. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
17. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
18. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
Wong SF
Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
[TBL] [Abstract][Full Text] [Related]
19. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
20. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
